Don’t miss our keynote “AI and the Perpetual Research Cycle: Accelerating Drug Discovery through Enhanced Literature Analysis” by Mark Hahnel, Vice President of Open Research, Digital Science, at 08:30 – 09:00AM. 

Abstract:

This talk explores the transformative impact of Artificial Intelligence (AI) on the research lifecycle, with a focus on its application in accelerating drug discovery. It introduces the concept of the “Perpetual Research Cycle,” where AI facilitates the continuous flow from data to papers and knowledge, driving innovation in scientific research. The discussion will highlight how AI tools enhance critical stages of this cycle, particularly in literature analysis and review, which are fundamental to drug discovery.

The presentation will showcase specific AI-driven solutions that streamline systematic literature reviews, enable continuous monitoring of relevant publications, and enhance the precision and efficiency of data extraction from scientific literature. By automating and accelerating these processes, AI empowers researchers to derive deeper insights from vast amounts of scientific data, ultimately leading to faster and more effective drug discovery. The talk will also address key considerations for responsible AI implementation in research, ensuring trust, accuracy, and reliability in the quest for new therapies.

Meet our speaker

Mark Hahnel

Mark Hahnel is the VP of Open Research at Digital Science. He is the founder of Figshare, which he created whilst completing his PhD in stem cell biology at Imperial College London. He is passionate about open science and the potential it has to revolutionize the research community. Mark sits on the board of DataCite and the advisory board for Directory of Open Access Journals (DOAJ) and re3data.

The post AI in Drug Discovery Xchange – San Francisco 2025 appeared first on Digital Science.

Digital Science are delighted to be presenting the opening keynote, and facilitating a roundtable discussion at this year’s event.

Keynote: AI and the Perpetual Research Cycle: Accelerating Drug Discovery through Enhanced Literature Analysis

08:30 – 09:30, 25 June 2025

This talk explores the transformative impact of Artificial Intelligence (AI) on the research lifecycle, with a focus on its application in accelerating drug discovery. It introduces the concept of the “Perpetual Research Cycle,” where AI facilitates the continuous flow from data to papers and knowledge, driving innovation in scientific research. The discussion will highlight how AI tools enhance critical stages of this cycle, particularly in literature analysis and review, which are fundamental to drug discovery.

The presentation will showcase specific AI-driven solutions that streamline systematic literature reviews, enable continuous monitoring of relevant publications, and enhance the precision and efficiency of data extraction from scientific literature. By automating and accelerating these processes, AI empowers researchers to derive deeper insights from vast amounts of scientific data, ultimately leading to faster and more effective drug discovery. The talk will also address key considerations for responsible AI implementation in research, ensuring trust, accuracy, and reliability in the quest for new therapies.

Roundtable discussion: AI in Literature Reviews: Practical Strategies and Future Directions

11:20 – 12:20, 25 June 2025

Data Quality track

Join this interactive roundtable discussion to dive deeper into the role of AI in Systematic Literature Reviews for drug discovery. We’ll explore real-world applications, challenges, and best practices for integrating AI-driven tools into literature review workflows. Share experiences, discuss implementation strategies, and uncover new ways to leverage AI for faster, more precise evidence synthesis. Whether you’re exploring AI adoption or optimizing existing processes, this roundtable offers a collaborative space to exchange ideas and drive innovation in drug discovery research.

• Explore real-world applications, challenges, and best practices for AI-driven literature reviews in drug discovery
• Discuss implementation strategies and share experiences with AI integration in review workflows
• Uncover new ways to leverage AI for faster, more precise evidence synthesis
• Engage in a collaborative discussion on optimizing AI adoption and improving existing processes
• Exchange ideas and insights to drive innovation in drug discovery research

Dr Mark Hahnel

VP Open Research

Mark Hahnel is the VP Open Research at Digital Science. He is the founder of Figshare, which he created whilst completing his PhD in stem cell biology at Imperial College London. He is passionate about open science and the potential it has to revolutionize the research community. Mark sits on the board of DataCite and the advisory board for Directory of Open Access Journals (DOAJ) and re3data.

The post AI in Drug Discovery Xchange – Boston 2025 appeared first on Digital Science.

Digital Science are delighted to be sponsoring this year’s event, and will be presenting the opening keynote, as well as a roundtable in the Data Quality track.

Opening Address & Keynote Presentation: The Future of AI in Pharma: Accelerating Research Workflows with GenAI

08:30 – 09:00, 26 Sept 2024

In this keynote presentation, we will explore the transformative impact of Generative AI (GenAI) on research workflows and systematic literature reviews within the pharmaceutical industry. Traditional AI technologies like natural language processing and machine learning have long been used to streamline screening and data synthesis. Recent advances in Generative AI and multimodal capabilities offer new opportunities to accelerate workflows at every stage. But despite the promise of GenAI, the human perspective remains crucial. We will discuss the evolving roles of researchers and the need to balance automation with human insight. Attendees will learn about the latest GenAI-driven tools, their integration into current workflows, and the ethical considerations involved. Join us to discover how AI enhances research processes by augmenting human expertise, driving innovation, and advancing progress in pharma.

Robert McGrath

Co-founder and CEO of ReadCube (Digital Science)

ReadCube is a leader in scalable literature workflow solutions enhancing research driven teams by transforming the way scholarly literature is accessed, analyzed, monitored and interpreted. ReadCube’s adaptive suite of solutions, including the Papers reference manager, have helped millions of individuals and thousands of organizations globally. As a Digital Science solution, an AI-focused technology company providing innovative solutions to complex challenges, ReadCube works in partnership to advance global research for the benefit of society.
Before joining Digital Science, Robert worked on various software engineering projects at Microsoft, Franklin Templeton Investments, and early-stage software startups. He earned a degree in Computer Science from Harvard University.

Roundtable: How can we bring fact-based knowledge and language together in AI applications for drug discovery?

11:20 – 12:20, 26 Sept 2024

• What are the primary challenges and benefits of implementing generative AI in drug discovery processes?
• What are some current measures to ensure a trustworthy data layer for AI applications? 
• What are the most promising applications of Generative AI for expediting the process and accuracy of drug discovery?
• What are the risks of AI-driven applications for the pharma space, such as ensuring results are compliant with legal and regulatory requirements? 
• Previous experiments with methods such as RAG, NL2SPARQL, graph embeddings and, what the results have been?

Dr Peter Doerr

Director Presales – Solution Architecture and Strategy, metaphacts

Peter Doerr is leading the presales team at metaphacts, a subsidiary of Digital Science specialized on Knowledge Graphs. After completing his PhD in mathematics, his career took him through IT and telecommunications where he worked in senior commercial roles as Vice President for Telefonica and Huawei before returning to a science-driven environment. At Digital Science, as VP corporate solutions, he worked closely with the largest customers to align applications and customer needs.

The post AI in Drug Discovery Xchange – San Francisco 2024 appeared first on Digital Science.

Digital Science are delighted to be exhibiting at the Innovation Roundtable Copenhagen 2023!

The Summit has a highly interactive format, combining insightful presentations with a variety of discussion sessions and ample time for informal networking, enabling you to meet and exchange experiences with other corporate executives from different industries.

Join Christian Beinhölzl for a presentation on Day 1 of the conference and both Mihai Gherge and Guido Kemeling for a roundtable discussion on Day 2 of the conference.

Using AI Enabled Discovery to Accelerate Innovation

Time and date: 13:00, 7th November

Join us to explore how AI-powered tech is revolutionizing the landscape of sustainable innovation in R&D, offering powerful solutions to some of the most pressing challenges faced by researchers and innovators today. Through case studies and practical applications, attendees will gain invaluable insights into harnessing the full potential of AI to drive impactful and sustainable advancements in research and development.

Christian Beinhölzl

Corporate Sales Manager (Europe)

How can AI become sufficiently reliable for science-driven businesses?

Date: 8th November

Join Mihai Gherge and Guido Kemeling for a roundtable discussion with Scientific Publications at Merck.

Mihai Gherghe

Corporate Product Solutions Manager

Guido Kemeling

Global Medical Excellence Lead

The post Innovation Roundtable Copenhagen 2023 appeared first on Digital Science.

Digital Science is delighted to announce that Dr Peter Dörr, SVP Dimensions Industrial Solution, will be giving the Keynote Presentation at this conference.

Time: 8:30 – 9:00am

Taming the beast: A one year vision on Generative AI in knowledge discovery on scientific literature and more
The keynote will emphasize the rapid evolution of Generative AI, commencing with GPT-2 in 2019 and progressing swiftly through GPT-3 to the recent introduction of ChatGPT and GPT-4. This transformation significantly impacted data science and innovation departments worldwide, particularly those in research-driven sectors like life sciences and pharmaceuticals. Our talk will give Digital Science’s perspective on this dynamic technological landscape, projecting past experiences into the future to formulate a vision for the coming year. We will highlight the rise of open-source community efforts in developing efficient transformer models, enabling comprehensive analysis of scientific literature.
Additionally, underscoring the integration of symbolic AI and structured data, emphasizing the challenge of effectively harnessing AI’s potential while ensuring trust, reliability, cost-efficiency, and sustainability in the field of data science and innovation.

Dr Peter Dörr

SVP Dimensions Industrial Solution

Peter Dörr PhD is a business strategist with hands-on experience in sales, product marketing and product development. His experience expands over several industries including IT, consumer electronics to Knowledge and AI solutions for the pharma and other research intensive industries.
Peter is a regular speaker at events such as biotechX, Bio IT World, Reuters Pharma Europe. Digital innovation is his topic, and today that means above all how we can make existing knowledge more usable with the help of artificial intelligence. In his role at Digital Science he is an interface between customers, product development and professional services.

The post Augmented Intelligence in Drug Discovery Xchange Europe 2023 appeared first on Digital Science.

Digital Science are delighted to be Platinum Sponsors of BioTechX Europe!

Europe’s largest biotechnology congress bridges the gap between pharma, academia and clinicians to foster meaningful collaborations. With 17 tracks of high-level content, the agenda covers everything from the use and management of multiomic data to the development of personalised therapies and the actual generation of the data.

Join Dr Peter Dörr for the following session on Day 1 of the conference.

4 October @ 17:05 in the Keynote Room

Track: AI in Drug Development and Discovery

From symbolic AI to generative AI and back: new knowledge discovery workflows for text and structured data sources

Artificial intelligence is on everyone’s mind – especially since ChatGPT hit the world. While generative AI opens up seemingly endless new possibilities, the limitations, especially for scientific work, are now well known. With the Dimensions AI Assistant,Digital Science brings its first discovery solution that uses generative AI, always in direct connection with the scientific literature to gain insights in a reliable way. Thus, control remains with the users, which is the basis for responsible use of this new technology. In the future, the link with classic symbolic AI, such as in our Dimensions Knowledge Graph, will also play a major role. Here, curated knowledge is combined with generative AI, making it easier and more effective to discover such scientific literature containing the secrets drug developers are looking for.

Dr Peter Dörr, Senior Vice President, Digital Science

Dr Peter Dörr

Senior Vice President, Digital Science

Peter is currently the Senior Vice President for Dimensions Industrial Solutions at Digital Science, having joined in May 2020. Prior to this, Peter was Director of Sales Strategy and Operations at Huawei Germany (2016-2019) and VP Devices at Telefonica o2 Germany. He has also worked for Electronic Data Systems as their Business Development Manager from 2001-2004, as well as a Research Assistant in Applied Mathematics at the

The post BioTechX Europe 2023 appeared first on Digital Science.